IDL Biotech Q1: First comment

Research Note

2020-04-23

08:46

In the first quarter, IDL reported sales and EBIT in line with our expectations. The company guides for a remarkable drop in net sales in Q2 due to effects of the corona crisis. We provide a short comment on the Q1 release and plan return with a research update within the next days.

LS

Ludvig Svensson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.